ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,166.76
0.03%
Dow Jones
39,169.52
0.13%
Gold vs US Dollar
2,330.37
-0.08%
Brent Oil
86.695
0.19%
Bitcoin
62,956.96
0.17%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) News

Argen X (ARGX)

Argen X SE
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ARGX
DateTimeSourceHeadlineSymbolCompany
25/06/202421:30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingEU:ARGXArgen X SE
21/06/202421:50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
17/06/202406:00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024EU:ARGXArgen X SE
04/06/202406:00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceEU:ARGXArgen X SE
09/05/202406:00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
07/05/202422:30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersEU:ARGXArgen X SE
07/05/202406:00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceEU:ARGXArgen X SE
02/05/202406:00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
16/04/202406:00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
27/03/202406:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
26/03/202420:00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
26/03/202406:00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
07/03/202421:01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
29/02/202406:00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
26/02/202406:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
22/02/202406:00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
20/02/202406:00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
18/01/202406:00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
08/01/202406:00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
02/01/202406:00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceEU:ARGXArgen X SE
20/12/202306:00GlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusEU:ARGXArgen X SE
28/11/202306:00GlobeNewswire Inc.argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
16/11/202312:40GlobeNewswire Inc.argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisEU:ARGXArgen X SE
01/11/202306:00GlobeNewswire Inc.argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsEU:ARGXArgen X SE
01/11/202306:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
31/10/202306:00GlobeNewswire Inc.argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
24/10/202306:00GlobeNewswire Inc.argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023EU:ARGXArgen X SE
21/09/202306:00GlobeNewswire Inc.argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia GravisEU:ARGXArgen X SE
15/09/202306:00GlobeNewswire Inc.argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia GravisEU:ARGXArgen X SE
30/08/202306:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
 Showing the most relevant articles for your search:EU:ARGX

Your Recent History

LSE
ENET
Ethernity Networks
LSE
BARC
Barclays
LSE
LLOY
Lloyds Banking
LSE
ZED
Zenova
LSE
ALBA
Alba Mineral Resources
LSE
MNL
Manchester & London Inve...
LSE
PPP
Pennpetro Energy
LSE
AAZ
Anglo Asian Mining
LSE
ITV
Itv
LSE
OSB
Osb
LSE
TERN
Tern
LSE
HBR
Harbour Energy
LSE
I3E
I3 Energy
LSE
DIG
Dunedin Income Growth In...
LSE
PFC
Petrofac
LSE
SNG
Synairgen
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved